Pregabalin Market size is forecast to reach $890 Million by 2025, growing at a CAGR of 3.67% during the forecast period 2020-2025. Pregabalin, marketed under the brand name Lyrica among others, is a medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome, and generalized anxiety disorder. Its use in epilepsy is as an add-on therapy for partial seizures. When used before surgery, it reduces pain but results in greater sedation and visual disturbances. Pregabalin dosage is usually oral. Rising prevalence of diabetes, HIV, cancer, epilepsy, fibromyalgia, and other such disorders among the geriatric population suffering from neuropathic diabetes and major technological advancements in the manufacturing process of pregabalin has resulted in a surge in demand of Pregabalin across the globe. Major healthcare investments by big firms and various product launches by key glove manufacturers like Cipla Limited are some other factors driving the growth of the market. Pregabalin Market Analysis is based on application, end user and geography.
Report Coverage
The report: “Pregabalin Market Forecast (2020-2025)”, by IndustryARC, covers an in-depth analysis of the following segments of the Pregabalin Market.
By Application: Epilepsy, Neuropathic Pain, Fibromyalgia, Generalized Anxiety Disorder
By End User: Research Institute, Pharmaceutical Company and Others
By Geography: North America, Europe, Asia Pacific, and Rest of the World.
Key Takeaways
- North America dominated the Pregabalin Market in the year 2019 owing to growing prevalence of diseases like neuropathic diabetes and HIV among the geriatric population, presence of well-developed healthcare infrastructure and presence of key market players. The Pregabalin Market scope for different regions will be provided in the final report.
- Rapidly growing incidences of diseases like epilepsy and cancer, as well as increasing awareness about health have helped in significant growth of Pregabalin Market. Innovation and progress of Pregabalin manufacture and increase in research and development of drugs by the key market players of the Pregabalin Industry in upcoming years is estimated to drive the industry growth during the forecast period 2020-2025.
- Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Pregabalin Market Research report.
- Stringent government regulations on manufacture and sales of pregabalin in many regions and competition from various biosimilars is anticipated to hamper the market growth of the Pregabalin Industry.
Application - Segment Analysis
Epilepsy held the largest share in the application segment of Pregabalin Market in 2019 and is estimated to grow at a CAGR of 4.03% during the forecast period 2020-2025. It is estimated that about 1.2 percent of U.S. people have active epilepsy. This comes out to about 3.4 million people nationwide — and more than 65 million globally. The demand for proper treatment of epilepsy is driving growth of this segment. Neuropathic Pain segment secured the second largest share in 2019. The prevalence of likely neuropathic pain is 1.9% (S-LANSS) and 3.4% (DN4) and that of possible neuropathic pain is 5.8% (S-LANSS) and 8.1% (DN4). Pregabalin is required for neuropathic pain owing to its relative reliability, easy use, and high tolerance in patients with neuropathic pain. As a successor of gabapentin, pregabalin has been shown to be effective in several models of neuropathic pain, incisional injury, and inflammatory injury. Epilepsy is set to be the fastest growing segment and is estimated to register the highest CAGR during the forecast period 2020-2025, owing to increase in its treatment using pregabalin and innovation of better technological treatment using pregabalin.
End User - Segment Analysis
Pharmaceutical companies hold the major share in the end user segment of Pregabalin Market in 2019. The US Food and Drug Administration (FDA) has approved nine generic versions of Pfizer’s nerve pain drug Lyrica (pregabalin), which are the first generics approved for the medication. Increased cases of diseases like epilepsy has resulted in demand for their proper treatment, particularly in the form of pregabalin. New medications have been developed by various pharmaceutical companies and are used to regulate neuropathic pain caused by diabetic peripheral neuropathy. Furthermore, they can also manage symptoms of postherpetic neuralgia, fibromyalgia and neuropathic pain related to spinal cord injury. Pharmaceutical companies’ segment is poised to continue dominating the market with the highest CAGR during the forecast period 2020-2025, owing to increasing investment in manufacturing and research and developments of products of Disposable Medical Examinations Market.
We also publish more than 100 reports every month in "Lifesciences and Healthcare”, Go through the Domain if there are any other areas for which you would like to get a market research study."
Comments
Post a Comment